Kazia Therapeutics (NASDAQ: KZIA), today provided a clinical update from its ongoing Phase 1b study evaluating paxalisib in combination ...
Kazia Therapeutics (NASDAQ: KZIA), today provided a clinical update from its ongoing Phase 1b study evaluating paxalisib in combination with pembrolizumab and chemotherapy in patients with late-stage ...
Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 months Notable responses were ...
1. Adjuvant carboplatin intensified chemotherapy was superior to standard chemotherapy in improving survival outcomes in patients with high-risk, early-stage, triple-negative breast cancer. Study ...
TOKYO--(BUSINESS WIRE)-- Incyte Biosciences Japan G.K. today announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz ® (retifanlimab) in combination with carboplatin and ...
Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial In this phase III trial, ...
New findings from this investigational study build on the strength of RYBREVANT® (amivantamab-vmjw) in non-small cell lung cancer and broadens its potential across additional solid tumors RARITAN, N.J ...
The FDA granted a first-ever approval for a first-line therapy for anal cancer to the PD-1 inhibitor retifanlimab (Zynyz), the agency announced Thursday. The approval stipulates use in combination ...
University of Arizona researchers devised a new method to deliver cancer chemotherapy drugs to pancreatic and breast cancer tumors more effectively and with less damage to healthy tissues than ...
Please provide your email address to receive an email when new articles are posted on . Survival outcomes did not differ for patients with HNSCC who received radiotherapy with carboplatin-paclitaxel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results